Duality of angiotensin II receptors and stroke and cancer risk: Is there a link;Dualite des recepteurs de l'angiotensine II et risque d'accidents vasculaires cerebraux et de cancer: Quels liens entre eux?

Presse Medicale

Volumn 28, Issue 17, 1999, Pages 918-922

  Fournier, Albert ^a,b   Ghitu, A ^a   Darabont, R ^a   Mazouz, H ^a   Makdassi, R ^a   Canaple, S ^a   Rosa, A ^a   Fernandez, L A ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b Hopital Sud   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ZABICIPRILAT; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR;

ANGIOGENESIS; BRAIN ISCHEMIA; CANCER RISK; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; DRUG MECHANISM; HEART INFARCTION; HUMAN; REVIEW; STROKE; ARTICLE; CEREBROVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; NEOPLASM; RISK FACTOR;

ANGIOTENSIN II; CEREBROVASCULAR DISORDERS; HUMANS; NEOPLASMS; RECEPTORS, ANGIOTENSIN; RISK FACTORS;

EID: 0033129315     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Hanson L, Hedner T, Lindholm L et al. The Captopril Prevention Project (CAPP) in hypertension. Final results. 17th Scientific meeting of the International Society of Hypertension, 7-11 June, 1998, Amsterdam.
2. Lever AF, Hole DJ, Gillis CR et al. Do inhibitors of angiotesin-1-converting enzyme protect against risk of cancer? Lancet 1998 ; 352:179-84.
3. Psaty B, Smith N, Siscovick D, Furberg C. Health outcomes associated with antihypertensive therapies used as just live agents. A systematic review and metaanalysis. JAMA 1997 ; 277:719-45.
4. Brown M, Brown J. Does angiotensin II protect against strokes ? Lancer 1986 ; ii:427-9.
5. Fernandez L, Caride V, Twickler J, Galardy R. Renin-angiotensin and development of collateral circulation after renal ischemia. Am J Physiol 1982 ; 243:H869-75.
6. Fernandez L, Spencer D, Kaczmar T. Angiotensin II decreases mortality rate in gerbils with unilateral carotid ligation. Stroke 1986 ; 17:82-5.
7. Kaliszewski C, Fernandez L, Wicke J. Differences in mortality rate between abrupt and progressive carotid ligation in the gerbil : role of endogenous angiotensin II. J Cerebral Blood Flow and Metab 1988 ; 8:149-54.
8. Fernandez L, Caride V, Strömberg C, Näveri L, Wicke J. Angiotensin AT2 receptor stimulation increases survival in gerbils with abrupt unilateral carotid ligation. J Cardiovasc Pharmacology 1994 ; 24:937-40.
9. Nelissen-Vrancken HJ, Boudier HA, Daemen MJ, Smits JF. Antihypertensive therapy and adaptive mechanisms in peripheral ischemia. Hypertension 1993 ; 22:780-8.
10. Safar M, London C. The arterial system in human hypertension. In: Swales JD, ed. Textbook of hypertension. Oxford: Blackwell Sc 1994 ; 85-102.
11. Fernandez L, Twickler J, Mead A. Neovascularization produced by angiotensin II. J Lab Clin Med 1985 ; 105:141-5.
12. Siragy H, Carey R. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 1997 ; 100:264-9.
13. Song K, Allen A, Paxinos G, Mendelsohn F. Angiotensin II receptor subtypes in rat brain. Clin Exp Pharmacol Physiol 1991 ; 18:93-6.
14. Liu YH, Yang XP, Sharov VC et al. Effect of angiotensin converting enzyme inhibitor and angiotensin II type 1 receptor antagonist in rats with heart failure. Role of kinin and angiotensin II type 2 receptor. J Clin Invest 1997 ; 99:1926-35.
15. Pitt B, Segal R, Martinez FA, Meuners G et al. on behalf of the ELITE study investigators X: Randomized trial of losartan versus captorpil in patients over 65 with heart failure. (Evaluation of Losartan in the Elderly study ELITE). Lancet 1997 ; 349:747-52.
16. Rump LC, Oberhauser V, Schwertfeger E, Schollmeyer P. Experimental evidence to support ELITE. Lancet 1998 ; 351:644-5.
17. Fournier A, Achard JM, Fernandez LA. Losartan versus captopril in elderly patients with heart failure. Lancet 1997 ; 349:1473-5 (letter).
18. Pahor M, Gurannik JM, Salive ME, Corti MC, Carbonin P, Havlik RJ. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996 ; 9:695-9.
19. Jick H, Jick S, Derby LE, Vasilakis C, Meyers MW, Meier CR. Calcium-channel blockers and risk of cancer. Lancet 1997 ; 349:525-8.
20. Le Noble FAC, Kessels-van-Wilick LC, Hacking WIG, Slaaf DW, Oude Egbrink MG, Struijker-Boudier HA. The role of angiotensin II and prostaglandins in arcade formation in a developping microvasular network. J Vasc Res 1996 ; 33:480-8.
21. Aziza A, Fernandez LA, Inagami T, Manuelidis E. Renin in glioblastoma multiform and its role in neovascularization. Am J Clin Pathol 1988 ; 90:437-41.
22. Lindop GB, Leckie BJ, Mimran A. Renin secreting tumors. In: Robertson JIS, Nicholls GM, eds. The renin angiotensin system. London: Gower Medical, 1993 ; 54.
23. Inwang ER, Puddefoot JR, Brown CL. Angiotensin II type 1 receptor in human breast tissues. Br J Cancer 1997 ; 75:1279-83.
24. Taylor GM, Cook HT, Sheffield EA, Hanson C, Peart WS. Renin in blood vessels in human pulmonary tumors. Am J Pathol 1988 ; 130:543-51.
25. Lyall F, Dornan ES, McQueen J, Boswell F, Kelly M. Angiotensin II increases proto-oncogene expression and phosphoinositide turnover in vascular smooth muscle cells via angiotensin II AT1 receptor. J Hypertens 1992 ; 10:1463-9.
26. Reddy MK, Baskaran K, Molteni A. Inhibitors of angiotensin-converting enzyme modulate mitosis and gene expression in pancreatic-cancer cells. Proc Soc Exp Biol Med 1995 ; 210:221-6.
27. Volpert OV, Ward WF, Lingen M. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996 ; 98:671-9.
28. Hii SI, Nicol DL, Gotley DC, Thompson LC, Green MK. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 1998 ; 77:880-3.
29. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induced acquired drug resistance. Nature 1997 ; 390:335-6.
30. Munzenmaier DH, Freene AS. Opposing actors of angiotensin II on microvascular growth and arterial pressure. Hypertension 1996 ; 27:760-5.
31. Olsen JH. Interpretation in drug epidemology. Lancet 1998 ; 312:162-3.